Ravi Salgia to Cell Proliferation
This is a "connection" page, showing publications Ravi Salgia has written about Cell Proliferation.
Connection Strength
1.773
-
MerTK Drives Proliferation and Metastatic Potential in Triple-Negative Breast Cancer. Int J Mol Sci. 2024 May 08; 25(10).
Score: 0.138
-
Lysocardiolipin acyltransferase regulates NSCLC cell proliferation and migration by modulating mitochondrial dynamics. J Biol Chem. 2020 09 18; 295(38):13393-13406.
Score: 0.106
-
Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell lines. Int J Oncol. 2020 07; 57(1):80-86.
Score: 0.104
-
SOX9: The master regulator of cell fate in breast cancer. Biochem Pharmacol. 2020 04; 174:113789.
Score: 0.102
-
MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale. Mol Cancer Ther. 2017 04; 16(4):555-565.
Score: 0.084
-
TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer. Cancer Sci. 2017 Mar; 108(3):488-496.
Score: 0.084
-
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma. Sci Rep. 2016 09 13; 6:32992.
Score: 0.081
-
Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer. Sci Rep. 2015 Jun 15; 5:10641.
Score: 0.074
-
MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PLoS One. 2014; 9(9):e105919.
Score: 0.071
-
Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer. Mol Cancer Ther. 2014 Mar; 13(3):576-84.
Score: 0.067
-
Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. Cancer Res. 2014 Feb 01; 74(3):884-95.
Score: 0.067
-
Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides. Cancer Lett. 2014 Feb 01; 343(1):14-23.
Score: 0.066
-
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target. PLoS One. 2013; 8(7):e67668.
Score: 0.065
-
A novel classification of lung cancer into molecular subtypes. PLoS One. 2012; 7(2):e31906.
Score: 0.059
-
NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases. Leukemia. 2011 Feb; 25(2):281-9.
Score: 0.054
-
Protein kinase C beta in malignant pleural mesothelioma. Anticancer Drugs. 2008 Oct; 19(9):841-8.
Score: 0.047
-
Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res. 2008 Jan 01; 68(1):132-42.
Score: 0.044
-
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res. 2005 Mar 15; 11(6):2312-9.
Score: 0.037
-
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005 Jul 08; 225(1):1-26.
Score: 0.036
-
MicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4/FOXM1/RRM2 axis. Mol Cancer. 2023 01 04; 22(1):1.
Score: 0.031
-
Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer. Mol Cancer Ther. 2021 10; 20(10):1820-1835.
Score: 0.028
-
MicroRNA-1: Diverse role of a small player in multiple cancers. Semin Cell Dev Biol. 2022 04; 124:114-126.
Score: 0.028
-
Targeting RLIP with CRISPR/Cas9 controls tumor growth. Carcinogenesis. 2021 Feb 11; 42(1):48-57.
Score: 0.028
-
Therapeutic targeting of miRNA-216b in cancer. Cancer Lett. 2020 08 01; 484:16-28.
Score: 0.026
-
Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer. Cell Commun Signal. 2019 12 16; 17(1):167.
Score: 0.025
-
Loss of H2B monoubiquitination is associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma. Int J Cancer. 2017 08 15; 141(4):766-777.
Score: 0.021
-
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Lett. 2016 10 01; 380(2):494-504.
Score: 0.020
-
Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab. Mol Cancer Ther. 2016 09; 15(9):2175-86.
Score: 0.020
-
Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer. Oncotarget. 2016 Mar 22; 7(12):13621-33.
Score: 0.020
-
Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer. Oncogene. 2016 05 05; 35(18):2357-69.
Score: 0.019
-
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Mol Cancer. 2014 Oct 24; 13:242.
Score: 0.018
-
The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. PLoS One. 2014; 9(3):e91577.
Score: 0.017
-
Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer. Mol Cancer Ther. 2014 May; 13(5):1356-68.
Score: 0.017
-
Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation. PLoS One. 2012; 7(9):e45330.
Score: 0.015
-
Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB J. 2012 May; 26(5):2175-86.
Score: 0.015
-
An E3 ubiquitin ligase: c-Cbl: a new therapeutic target of lung cancer. Cancer. 2011 Dec 01; 117(23):5344-50.
Score: 0.014
-
Fyn: a novel molecular target in cancer. Cancer. 2010 Apr 01; 116(7):1629-37.
Score: 0.013
-
Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion. Int J Gynecol Cancer. 2008 Sep-Oct; 18(5):976-84.
Score: 0.011